Santarus Inc. is a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders. Yesterday the company received a USFDA approval for its New Drug application (NDA) of its product ZEGERID® with Magnesium Hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide) Chewable Tablets 40 mg/600 mg/700 mg and 20 mg/600 mg/700 mg; an immediate-release proton pump inhibitor (PPI).
Zegerid® Chewable Tablets are treatment for the following indications: treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), the short-term treatment (four to eight weeks) of erosive esophagitis diagnosed by endoscopy and active benign gastric ulcers, the short-term treatment of active duodenal ulcers and for maintenance of healing of erosive esophagitis.
Read more at Santarus Inc.'s News Release.
Comment Preview